nccRCC
Advertisement
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
A recent study that sought to characterize rare kidney tumors has identified novel biomarkers in nccRCC subtypes.
Dr. Apolo shares the trials in progress she presented at this year's meeting, including SMART, LASER, and E-VIRTUE.
Dr. Albiges comments on the latest data from the nccRCC trial KEYNOTE-B61, including an extended follow-up analysis.
The study sought to better understand the effects of first-line systemic therapy in metastatic ChRCC.
Dr. Nguyen shares an ongoing study of combination tivozanib and nivolumab in advanced non-clear cell renal cell carcinoma.
Dr. Doshi and colleagues designed an analysis of patients with metastatic ChRCC to better understand first-line therapy.
IO/IO and IO/TKI immune combination therapies are common in the first-line treatment of renal cell carcinoma.
In patients with RCC, around 20% demonstrate non-clear cell histology, including various histology types.
The ARON-1 study investigated the efficacy of 1L treatment with TKIs versus IO-based combinations in patients with pRCC.
The investigators found significant differences in OS and recurrence-free survival across the histological subtypes.
RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Dr. Plimack comments on long-term survival data from nivolumab/ipilimumab in the CheckMate 214 study as well as other data.
Researchers noted that following first-line TKI therapy, effective subsequent treatment options for nccRCC were unclear.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.